Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

News | Pharmaceuticals | September 12, 2017

September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in...

New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC | September 12, 2017

September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with...

CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC | September 12, 2017

September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk...

COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies | September 12, 2017

September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with...

Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017

September 11, 2017 — Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced...

EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation | September 01, 2017

September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with...

Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies | August 28, 2017

August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc. announced results from an analysis of real-world data...

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies | August 18, 2017

August 18, 2017 — Medtronic plc announced a global randomized...

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies | August 16, 2017

August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI)...

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies | August 03, 2017

August 3, 2017 — Abbott recently announced the first patient has been enrolled in a...

Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies | July 25, 2017

July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs)...

Alere point of care POC testing for INR
News | Point of Care Testing | July 17, 2017 | Dave Fornell

July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is...

long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies | July 12, 2017

June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet...

Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension | July 05, 2017

July 5, 2017 — Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of...

Overlay Init